logo
  

AbbVie Brings VENCLEXTA Plus Obinutuzumab To Chronic Lymphocytic Leukemia Patients In Quebec

AbbVie (ABBV) has reached an agreement with the pan-Canadian Pharmaceutical Alliance for VENCLEXTA in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia. Following the agreement, Quebec is the first province to reimburse the combination treatment.

VENCLEXTA, in combination with obinutuzumab, is the third indication for VENCLEXTA for the treatment of chronic lymphocytic leukemia, a first-in-class B-cell lymphoma-2 inhibitor.

VENCLEXTA is jointly commercialized by AbbVie and Genentech in the U.S. and by AbbVie outside of the U.S.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Home improvement company Lowe's and pet retailer Petco Health and Wellness Co. are set to launch a pilot store-in-store program whereby a total home solution will be offered to customers by bringing home improvement as well as pet care products, services and expertise together under the same roof. Chevron Corporation (CVX) reported fourth quarter profit of $5.1 billion or $2.63 per share, compared to a loss of $665 million or $0.33 per share, previous year. The company's U.S. upstream operations earned $2.97 billion, compared to $101 million, a year ago. The company said the improvement was primarily... While reporting financial results for the fourth quarter on Friday, Colgate-Palmolive Co. (CL) initiated its earnings and sales growth guidance for the full-year 2022. For fiscal 2022, the company now expects earnings per share to grow in double-digit percentage and adjusted earnings per share growth...
Follow RTT